Oramed Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ORMP Oramed Pharmaceuticals Inc
GOTU Gaotu Techedu Inc
SGDVV Safe & Green Development Corp
GLBZ Glen Burnie Bancorp
PHAR Pharming Group NV
CARD Max Auto Industry -3X Inverse Leveraged ETN
HIW Highwoods Properties Inc
HFRO Highland Opportunities and Income Fund
HDV iShares Core High Dividend ETF
HDELY Heidelberg Materials AG

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Oramed Pharmaceuticals Inc. is a pharmaceutical company, which is engaged in the research and development of pharmaceutical solutions with its technology platform. Its POD (Protein Oral Delivery) technology has been designed to protect orally delivered proteins from detrimental enzymatic activity within the gastrointestinal tract and to enhance their absorption across the intestinal wall. Its pipeline includes ORMD-0801 diabetes, ORMD-0901, and ORMD-0801 non-alcoholic steatohepatitis (NASH). Its flagship product, ORMD-0801, allows insulin to travel from the gastrointestinal tract via the portal vein to the liver. It is conducting Phase III trials in patients with type 2 diabetes. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone, that stimulates the secretion of insulin from the pancreas. It is also engaged in the research and development of an oral vaccine for COVID-19 through its subsidiary, Oravax Medical Inc.


Last Trade
0.15 (5.70%)
B/A Size

Market Hours

Closing Price
Day's Change
0.00 (0.00%)
Bid close
Ask close
B/A Size
Day's High
Day's Low

10-day average volume:

Rivian, Lucid and Fisker navigate a 'treacherous road' as they struggle to match Tesla's success

12:31 pm ET May 13, 2023 (MarketWatch)

By Claudia Assis

EV startups are facing challenges on path to sustainable production and scale, analyst says

It was always going to be difficult.

Ramping up production of a new product, using relatively new technology, is a tall order in the best of times. Electric-vehicle startups Rivian Automotive Inc. (RIVN), Fisker Inc (FSR) and Lucid Group Inc. (LCID) are finding out that it is extra hard in the middle of economic uncertainty, lingering supply-chain worries, rising interest rates and less patient investors.

Earlier this week, Fisker and Lucid cut their production outlooks for the year. Rivian kept its 2023 production guidance intact, but hasn't kept the critics at bay, with one analyst comparing Rivian's trajectory going forward as walking "a tightrope."

See also:Fisker cuts production, posts wider loss than expected

Recent months serve as a reminder that the story of any EV startup, with Tesla Inc. (TSLA) being the "only confirmed success thus far," will consist of "inevitable waves (ups/downs) as investor focus to remain on the mosaic of execution/milestones on the treacherous road to sustainable production and scale," Chris McNally at Evercore ISI said in a recent note.

Don't miss:Lucid stock drops 9% after EV startup dials down production guidance

The environment in which a lot of the EV startups launched operations is "vastly different from today," said Michelle Krebs, an analyst with Cox Automotive. Interest rates were low, there was lots of investor money, and the companies captured those flows.

"That money is not as readily available now," Krebs said. "Investors get impatient and they want to see results, and (this week's results) are not it."

The startups also underestimated the amount of cash required to get an EV maker off the ground, and they may be running out of money at a time when it is harder to come by, Krebs said.

Legacy automakers can afford to lose money on EVs -- Ford Motor Co. (F) has said it expects its EV unit to lose $3 billon this year -- because they already have steadier streams of revenue from elsewhere, she said. And, of course, Tesla "took a lot of time to turn around, too," and about a decade before it was profitable.

Lordstown Motors Corp. (RIDE) last week warned it could run out of cash as its relationship with Taiwanese electronics contract maker Foxconn appears to have soured.

The difficulties of launching a vehicle are not unique to electric cars, but the relatively new technology adds another layer of complexity, Krebs said.

Ford has had years of recalls and problems with its Explorer SUV. As far as EVs, Tesla and General Motors Co. (GM) have had their fair share of recalls with their vehicles, with GM earlier this year recalling every Chevy Bolt it ever made to swap batteries.

In March, consultants at J.D. Power found that recalls and service times for EVs resulted in the first dip for its customer-service satisfaction index in nearly 30 years And consumer satisfaction with car services among EV owners is lower than among owners of traditionally powered vehicles, J.D. Power said.

-Claudia Assis

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

May 13, 2023 12:31 ET (16:31 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.